Back to Search
Start Over
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung
- Source :
- Scientia, Lazar, V, Raynaud, J, Magidi, S, Bresson, C, Martini, J F, Galbraith, S, Wunder, F, Onn, A, Batist, G, Girard, N, Lassen, U, Pramesh, C S, Al-Omari, A, Ikeda, S, Berchem, G, Blay, J Y, Solomon, B, Felip, E, Tabernero, J, Rubin, E, Philip, T, Porgador, A, Berindan-Neagoe, I, Schilsky, R L & Kurzrock, R 2022, ' Comorbidity between lung cancer and COVID-19 pneumonia : role of immunoregulatory gene transcripts in high ACE2-expressing normal lung ', Therapeutic Advances in Medical Oncology, vol. 14, pp. 1-15 . https://doi.org/10.1177/17588359221133893
- Publication Year :
- 2022
- Publisher :
- SAGE Publications, 2022.
-
Abstract
- ACE2 expression; COVID-19; Cancer Expresión ACE2; COVID-19; Cáncer Expressió ACE2; COVID-19; Càncer Background: SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression of angiotensin-converting enzyme 2 (ACE2, the SARS-CoV-2 receptor) and of immunoregulatory genes in normal lung tissues from patients with non-small cell lung cancer (NSCLC). Methods: This study used the transcriptomic and the clinical data for NSCLC patients generated during the CHEMORES study [n = 123 primary resected (early-stage) NSCLC] and the WINTHER clinical trial (n = 32 metastatic NSCLC). Results: We identified patient subgroups with high and low ACE2 expression (p = 1.55 × 10−19) in normal lung tissue, presumed to be at higher and lower risk, respectively, of developing severe COVID-19 should they become infected. ACE2 transcript expression in normal lung tissues (but not in tumor tissue) of patients with NSCLC was higher in individuals with more advanced disease. High-ACE2 expressors had significantly higher levels of CD8+ cytotoxic T lymphocytes and natural killer cells but with presumably impaired function by high Thymocyte Selection-Associated High Mobility Group Box Protein TOX (TOX) expression. In addition, immune checkpoint-related molecules – PD-L1, CTLA-4, PD-1, and TIGIT – are more highly expressed in normal (but not tumor) lung tissues; these molecules might dampen immune response to either viruses or cancer. Importantly, however, high inducible T-cell co-stimulator (ICOS), which can amplify immune and cytokine reactivity, significantly correlated with high ACE2 expression in univariable analysis of normal lung (but not lung tumor tissue). Conclusions: We report a normal lung immune-tolerant state that may explain a potential comorbidity risk between two diseases – NSCLC and susceptibility to COVID-19 pneumonia. Further, a NSCLC patient subgroup has normal lung tissue expressing high ACE2 and high ICOS transcripts, the latter potentially promoting a hyperimmune response, and possibly leading to severe COVID-19 pulmonary compromise. FundingThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research leading to these results on the CHEMORES study data, an initiative from the Chemotherapy resistance consortium, has received funding from the European Union Sixth Framework (FP6) Integrated Project. The research on the WINTHER trial data leading to these results has received funding from the European Union Seventh Framework Program (FP7) (WINTHER: FP7/2007-2013 under grant agreement n°306125). WINTHER, an initiative from the WIN Consortium, was funded in part by ARC Foundation for cancer research (France), Pfizer Oncology, Lilly France SAS, and Novartis Pharmaceuticals Corporation. Funded in part by The FERO/J.P. Morgan Private Bank Clinical Oncology Research Grant, National Cancer Institute grant P30 P30-CA023100 (RK), Israeli Science Foundation grant 1188/16 (ER), Instituto Salud Carlos III – Programa Rio Hortega Contract grant CM15/00255 (EF) and Canadian Institutes for Health Research (grant MOP-142281, GB) and the Canadian Cancer Society (grant 703811, GB).
- Subjects :
- fenómenos genéticos::expresión génica::transcripción genética [FENÓMENOS Y PROCESOS]
ACE2 expression
COVID-19
Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]
Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES]
neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES]
COVID-19 (Malaltia)
transcriptomics
Transcripció genètica
Oncology
Comorbiditat
Pulmons - Càncer
epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA]
virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]
cancer
normal lung
Genetic Phenomena::Gene Expression::Transcription, Genetic [PHENOMENA AND PROCESSES]
Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH]
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Scientia, Lazar, V, Raynaud, J, Magidi, S, Bresson, C, Martini, J F, Galbraith, S, Wunder, F, Onn, A, Batist, G, Girard, N, Lassen, U, Pramesh, C S, Al-Omari, A, Ikeda, S, Berchem, G, Blay, J Y, Solomon, B, Felip, E, Tabernero, J, Rubin, E, Philip, T, Porgador, A, Berindan-Neagoe, I, Schilsky, R L & Kurzrock, R 2022, ' Comorbidity between lung cancer and COVID-19 pneumonia : role of immunoregulatory gene transcripts in high ACE2-expressing normal lung ', Therapeutic Advances in Medical Oncology, vol. 14, pp. 1-15 . https://doi.org/10.1177/17588359221133893
- Accession number :
- edsair.doi.dedup.....d5925932de3f74f03629c6fd6145d1f2